A phase 1b/2 trial of Gumatinib in patients with advanced solid tumors with MET mutations
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Gumarontinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Haihe Biopharma
- 24 Aug 2022 New trial record